Making the Most of the Clinical Toolbox: Improving Outcomes in HABP and VABP
Back to course
Asset Caption
The Society of Critical Care Medicine's Critical Care Congress features internationally renowned faculty and content sessions highlighting the most up-to-date, evidence-based developments in critical care medicine. This is a presentation from the 2020 Critical Care Congress held February 16-19, 2020, in Orlando, Florida, USA.
This program is supported by an educational grant from Merck & Co., Inc.
Learning Objectives
- Explain the evolving epidemiology and etiology of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)
- Discuss key safety and efficacy data for newer agents being used for the treatment of HABP and VABP
- Develop tailored treatment strategies for HABP and/or VABP that support the principles of antibiotic stewardship
- Coordinate with members of the multiprofessional care team to improve timely diagnoses
Welcome and Introductions
Marin H. Kollef
HABP and VABP: Epidemiology, Microbiology, and Clinical Consequences
Richard Wunderink
Considerations for Antiobiotic Therapy for MDR Infections in HABP and VABP
Debra Goff
New and Emerging Therapies: A Closer Look at the Data
Richard Wunderink
Individualizing Therapy to Support Antimicrobial Stewardship and Improved Outcomes
Marin Kollef
Concluding Remarks and Audience Q&A
Marin Kollef